Health insurer's stock rallies as it maintains financial targets despite recent Medicare Star Ratings challenges.
Singapore-based security firm Concorde International Group sees massive trading volume without any apparent news catalyst, prompting investor caution.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
Internal U.S. Army memo flags 'fundamental security' vulnerabilities in a key battlefield communications network, raising contract concerns.
Shares of the recently-listed marine fuel provider hit all-time lows on massive volume as the market reacts to unspecified executive shifts.
Blaze at the massive El Segundo facility, a key fuel supplier for Southern California, raises concerns over potential price impacts.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.